Skip to main
KMTS

KMTS Stock Forecast & Price Target

KMTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Kestra Medical Techs is a commercial-stage MedTech company that has developed the ASSURE Cardiac Recovery System, which includes the ASSURE wearable cardioverter defibrillator (WCD). The company has shown strong growth in its prescription volume, driven by market share gains and new account activations, and has a well-positioned salesforce and partnerships for further expansion. We expect continued revenue growth and gross margin expansion, warranting a Buy rating and $32 price target based on 10x our 12-24 month revenue forecast, in light of KMTS's early stage of commercial ramp, high growth rate, and potential for further improvements in profitability, as well as a duopoly market and lengthy growth runway. Risks to our outlook include potential challenges in commercial execution, regulatory decision, and competition.

Bears say

Kestra Medical Techs is currently in the early stages of its commercial ramp and is experiencing high sales growth. However, there are risks to their commercial execution, as well as concerns about regulatory and reimbursement decisions, competition, and their balance sheet. Our Buy rating is based on a $32 price target, which is 10x our revenue forecast for the next 12-24 months.

KMTS has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kestra Medical Technologies Inc (KMTS) Forecast

Analysts have given KMTS a Buy based on their latest research and market trends.

According to 4 analysts, KMTS has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kestra Medical Technologies Inc (KMTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.